SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is facing intense market volatility and significant analyst downgrades following a weak bookings guidance reset and the disruptive impact of its new age verification rollout. The community remains deeply polarized, with many investors debating whether the current selloff offers a buying opportunity in a sticky platform or if persistent safety concerns and slowing growth justify further downside.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors digest a massive earnings beat, with the community actively debating whether the company's strong monetization and user growth can spark a sustained rally or if the stock will face typical post-earnings volatility. While bulls point to improved profitability and long-term data licensing potential as catalysts for a squeeze, bears remain skeptical, citing concerns over user engagement quality and historical patterns of post-report pullbacks.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is trending following the announcement of a $30 million private placement and a new licensing deal for an anti-IgE asset, which has triggered intense speculation regarding its potential for a short squeeze among retail traders. While some investors are highlighting the company's clinical pipeline and low float as catalysts for a major rally, others remain skeptical, pointing to the effective offering price and potential dilution risks.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is seeing significant market activity following a record-breaking fiscal quarter that featured double-digit revenue growth and a new $100 billion share buyback authorization. Investors are actively debating the leadership transition to incoming CEO John Ternus and the company's long-term growth outlook, with community discussion centered on supply chain constraints, margin pressure from memory costs, and anticipation for upcoming AI product reveals.

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing extreme volatility and a parabolic rally driven by a extremely low tradeable float, which has triggered an aggressive short squeeze as borrow fees have surged toward 1000%. The community is intensely debating the sustainability of this run, with many bullish traders focused on momentum and the potential for forced short covering, while skeptics point to the company's history of reverse splits and warn of an inevitable correction.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is experiencing significant bullish momentum driven by the upcoming presentation of its pancreatic cancer trial data at Digestive Disease Week, which has investors anticipating a major clinical breakthrough. Community sentiment remains overwhelmingly optimistic, with retail traders aggressively accumulating shares and discussing potential catalystsincluding trial expansions and upcoming gala eventsas the stock continues to trend on high volume.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian shares are surging following a robust quarterly performance that exceeded revenue and earnings expectations, bolstered by strong cloud growth and accelerated AI monetization. The community is actively debating whether this result signals a durable recovery for enterprise software or if the stock remains vulnerable to ongoing valuation and competition concerns.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is experiencing extreme volatility following a massive quarterly earnings beat that saw revenue triple and guidance raised, with the community divided between bulls viewing the pullback as a gift and bears warning of a potential bubble after a year of historic gains. Investors are closely monitoring the $6 billion share buyback announcement and the company's aggressive expansion into AI data center infrastructure as key indicators for whether the stock can maintain its upward trajectory.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global Holdings is trending following a strong first-quarter report where the company beat revenue estimates and raised its forward guidance, fueling community optimism around its accelerating AI-driven marketing growth. Investors are actively debating the sustainability of its 50% year-over-year revenue growth and debating the stock's potential for a short squeeze as they look for signs of a long-term re-rating phase.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digital is trending due to a wave of bullish analyst upgrades and price target increases following strong quarterly results that highlight the company's pricing power and sustained demand for AI-driven storage. While many in the community are celebrating this momentum as part of an AI infrastructure supercycle, others remain cautious, debating whether current valuations reflect a sustainable margin expansion or a temporary peak driven by overcrowded positioning.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tango Therapeutics (NASDAQ:TNGX) Trading Down 9.7% - Here's What Happened

Tango Therapeutics (NASDAQ:TNGX) Stock Price Down 9.7% - What's Next...

Stifel Nicolaus Issues Positive Forecast for Tango Therapeutics (NASDAQ:TNGX) Stock Price

Stifel Nicolaus increased their price target on shares of Tango Therapeutics from $24.00 to $40.00 and gave the company a "buy" rating in a report on Monday...

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Moderate Buy" by Brokerages

Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) has earned an average rating of "Moderate Buy" from the twelve research firms that are covering the firm, Marketbeat.com reports. One equities...

354,192 Shares in Tango Therapeutics, Inc. $TNGX Bought by Mass General Brigham Inc

Mass General Brigham Inc acquired a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing...

Tango Therapeutics (NASDAQ:TNGX) Reaches New 1-Year High - Should You Buy?

Tango Therapeutics (NASDAQ:TNGX) Hits New 52-Week High - What's Next...

Tango Therapeutics (NASDAQ:TNGX) Insider Adam Crystal Sells 38,460 Shares

Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) insider Adam Crystal sold 38,460 shares of the business's stock in a transaction dated Wednesday, April 15th. The stock was sold at an average...

Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells 38,460 Shares of Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) insider Adam Crystal sold 38,460 shares of the company's stock in a transaction dated Wednesday, April 15th. The shares were sold at an...

Tudor Investment Corp ET AL Acquires New Holdings in Tango Therapeutics, Inc. $TNGX

Tudor Investment Corp ET AL acquired a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the 3rd quarter, according to its most recent filing with the Securities...

Tango Therapeutics (NASDAQ:TNGX) Reaches New 52-Week High  - Here's What Happened

Tango Therapeutics (NASDAQ:TNGX) Reaches New 52-Week High - Should You Buy...

<ul class="summary-bullets"><li>Revolution announced positive data from its own experimental cancer drug daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma, earlier in the day.&nbsp;</li><li>Erasca is focused on developing therapies for cancers like Revolution.</li><li>The company has several names in its pipeline for pancreatic cancer including ERAS-0015 and ERAS-4001.</li></ul>Shares of Erasca Inc. (ERAS) fell 7% on Monday on the heels of rival Revolution Medicines’s (RVMD) positive study data in pancreatic cancer, applauded as a “game changer” by Wall Street. &nbsp;Erasca is also focused on developing therapies for cancers, including pancreatic ductal adenocarcinoma (PDAC), like Revolution. The company has several names in its pipeline for pancreatic cancer, including ERAS-0015 and ERAS-4001.Last month, Erasca entered into a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. (TNGX) to evaluate ERAS-0015, with Tango’s vopimetostat, in pancreatic cancer.Revolution said earlier in the day that its late-stage trial evaluating its experimental cancer drug daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma, who had been previously treated, demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival compared with standard chemotherapy.Patients treated with the drug lived a median of 13.2 months, compared with 6.7 months for those on chemotherapy, highlighting a meaningful benefit. The treatment was also generally well tolerated, with no new safety concerns reported, the company said. RBC Capital now sees daraxonrasib in metastatic pancreatic ductal adenocarcinoma as a "game-changer."RVMD shares were up 41% at the time of writing.<h2 class="st-heading-2">Analyst Take Away</h2>Jefferies called Revolution’s results in second-line pancreatic ductal adenocarcinoma "a clear win" for daraxonrasib, but kept the bar for Erasca unchanged. The firm kept its ‘Buy’ rating and $21 price target on Erasca shares.According to data from Koyfin, eight of the 10 analysts covering ERAS stock rate it ‘Buy’ or higher, while one rates it ‘Hold’ and one rates it ‘Strong Sell.’ The average 12-month price target on the stock is $18.10, representing a potential upside of 14% from current trading levels.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ERAS stock jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/ERAS">ERAS stock</a> has gained nearly 1,200% over the past 12 months, compared to <a href="https://stocktwits.com/symbol/RVMD">RVMD</a>’s 272% rally.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ima-stock-breaks-50dma-for-first-time-since-february/cZJ8drzRIur">IMA Stock Surges 24%, Breaks 50-DMA For First Time Since February – What's Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Erasca logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ERAS Stock Slumps Against RVMD Rally — Analyst Stays Bullish

Erasca is focused on developing therapies for cancers, including pancreatic ductal adenocarcinoma, like Revolution. 

Equity

Erasca is focused on developing therapies for cancers, including pancreatic ductal adenocarcinoma, like Revolution. 


Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Current Price	$21.62
Prev Close	$22.06
Open	$22.00
Dividend Yield	0.00%
50-Day Moving Average	$19.31
Beta	1.06
Avg. Volume	4.07M
PE Ratio	-25.01

52-Week High	$28.41
52-Week Low	$1.03
Market Capitalization	$3.08B
EPS (Annual)	-$0.8746
Price to Book	8.49
Revenue Per Employee	$455,357.66

TNGX
Tango Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TNGX News

TNGXTango Therapeutics Inc